Chrono Health Secures $2.3B to Build Predictive Health Network for 100 Million Users

SAN FRANCISCO — Chrono Health, a three-year-old healthcare infrastructure startup, announced a $2.3 billion Series C led by Sequoia Global and Temasek, with participation from GV, a]6z, and three unnamed sovereign wealth funds. The round values the company at $18 billion post-money.

The funding will fuel the deployment of Chrono Health's flagship product: the PulseSync Protocol, a decentralized biosignal prediction network that monitors continuous biometric data streams from wearable and edge-level sensors to forecast health anomalies up to 72 hours before clinical symptoms manifest.

How PulseSync Works

Unlike traditional wellness platforms that track metrics retrospectively, PulseSync ingests multi-modal biosignatures — heart rate variability, galvanic skin response, micro-expression patterns via camera, and ambient environmental data — through a mesh of distributed edge nodes deployed in homes, workplaces, and public spaces.

A proprietary on-device model, ChronoMind, runs lightweight inference locally before transmitting encrypted anomaly vectors to Chrono Health's prediction cloud. The cloud correlates individual baselines against population-level epidemiological models updated hourly.

"We are not a fitness tracker. We are a public health early-warning infrastructure," said Dr. Yuna Sato, Chrono Health's co-founder and CEO, in a statement. "PulseSync treats health as a signal processing problem, not a clinical one."

Commercial Traction

Chrono Health has signed binding contracts with Aetna Global, Cigna Employer Health, and Ping An Health, collectively covering 28 million lives. An additional 40 self-insured Fortune 500 employers — including two unnamed semiconductor companies — have signed Letters of Intent for workplace deployment.

The company's revenue model is B2B2C: Chrono Health charges insurers a per-member-per-month (PMPM) fee of $3.50 for access to the prediction dashboard and alert API, integrated directly into existing care management platforms via a HIPAA-compliant FHIR接口.

The Science Under the Hood

Chrono Health's core innovation is a temporal biosignature fusion algorithm that combines longitudinal wearable data with environmental context (air quality, noise levels, crowd density) to generate a 72-hour health trajectory for each subscriber.

In a peer-reviewed study published in Nature Digital Medicine in September, Chrono Health's model demonstrated:

• 78% sensitivity in predicting influenza-like illness onset 72 hours in advance
• 91% specificity in distinguishing stress-induced HRV fluctuations from pathological anomalies
• AUC-ROC of 0.89 across a cohort of 180,000 participants over 18 months

Competitive Landscape

Chrono Health competes with HealthIO (Series D, $800M valuation) and BioStream AI, both of which focus on retrospective health analytics. The predictive, protocol-based approach sets Chrono Health apart, according to analysts.

"Chrono Health is essentially building a GPS for human health — not showing you where you've been, but where you're going," said healthcare investor Priya Mehta of Oak HC/FT. "If the clinical data holds at scale, this becomes critical national infrastructure."

What's Next

Chrono Health will use the proceeds to expand its edge node manufacturing (currently produces 50,000 units/month in Shenzhen), grow its data science team from 340 to 800 engineers, and file for FDA Breakthrough Device Designation for three cardiovascular prediction models by Q1 2028.

The company plans to go public via a traditional IPO in late 2028, targeting a $40 billion valuation, pending clinical validation at the 1-million-subscriber milestone expected by mid-2028.